Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Keith Thompson

Clinical Commissioning Pharmacist, Royal Brompton & Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP

Contact Info

Email:
Keiththompson@nhs.net

Recent stories

  • Geneticist at the French National Institute for Health and Medical Research (Inserm) researches genetic diseases like cystic fibrosis

    Conventional therapies and emergent precision medicines for cystic fibrosis: challenges and opportunitiesSubscription

    30 NOV 2016

    Around 27 years ago, the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene – responsible for causing cystic fibrosis (CF) – marked a significant moment in the history of the condition. Despite the early promise of this target for gene therapy, a universally successful treatment has proven elusive in the ensuing years. While clinical trials involving gene therapy continue to make progress, the ‘magic bullet’ remains some way off. Survival continues to be diminis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.